PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
2424829-1	1986	The effects of Isoprinosine (ISO) on interleukin-2 (IL-2) production by human peripheral blood mononuclear cells (PBMC) were investigated.	Inosine Pranobex	29-32	interleukin 2	Homo sapiens	37-50	
2424829-0	1986	Effect of isoprinosine on sialylation of interleukin-2.	Inosine Pranobex	10-22	interleukin 2	Homo sapiens	41-54	
2469797-0	1988	Isoprinosine potentiation of human peripheral blood mononuclear cell response to mitogens: kinetics and effect on expression of the IL-2 receptor and the activity of interleukin 2.	Inosine Pranobex	0-12	interleukin 2	Homo sapiens	166-179	
2469797-4	1988	Increased interleukin-2 activity was detected in three out of nine supernatants from PHA activated mononuclear cells which were cultured in the presence of isoprinosine.	Inosine Pranobex	156-168	interleukin 2	Homo sapiens	10-23	
6207122-1	1984	Isoprinosine appeared to potentiate the production of interleukin 1 and interleukin 2 in cultures of lipopolysaccharide stimulated human monocytes and phytohemagglutinin stimulated cultures of blood mononuclear cells respectively at pharmacological drug levels.	Inosine Pranobex	0-12	interleukin 2	Homo sapiens	72-85	
2409037-6	1985	In the presence of ISO, ConA-induced lymphocyte proliferation, NK activity, neutrophil chemotaxis, and IL-2 production were restored to normal or near normal levels in 50 of the 55 (90.0%), 35 of the 41 (85.3%), 44 of the 52 (84.6%), and 25 of the 35 (71.4%) aging humans, respectively.	Inosine Pranobex	19-22	interleukin 2	Homo sapiens	103-107	
2581997-0	1985	Partial restoration of impaired interleukin-2 production and Tac antigen (putative interleukin-2 receptor) expression in patients with acquired immune deficiency syndrome by isoprinosine treatment in vitro.	Inosine Pranobex	174-186	interleukin 2	Homo sapiens	32-45	
2581997-0	1985	Partial restoration of impaired interleukin-2 production and Tac antigen (putative interleukin-2 receptor) expression in patients with acquired immune deficiency syndrome by isoprinosine treatment in vitro.	Inosine Pranobex	174-186	interleukin 2	Homo sapiens	83-96	
6190598-8	1983	The mechanism responsible for these effects is not known but IL-2 production by patient lymphocytes in vitro which was low for both RA (P less than 0.01) and SLE (P less than 0.02) increased significantly (P less than 0.05) when SLE lymphocytes were cultured with IPS.	Inosine Pranobex	264-267	interleukin 2	Homo sapiens	61-65